H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

H. Lundbeck A/S

Capstone Advisors focuses on acquiring, developing, and managing commercial and residential real estate.

Capstone Advisors

Kalderos aims to bring clarity and transparency to the complex world of drug discounts, facilitating the smooth operation of discount programs and ensuring funds flow seamlessly as intended to support safety-net providers, manufacturers, and patient access to care and treatments.

David DeVogel

Jeremy Docken

Jim Bonkowski

Kalderos

Neuro Vigor Therapeutics is a development stage company focused on reducing reactive aldehyde species, which are significant contributors to multiple diseases, trauma, and pain.

Neuro Vigor Therapeutics

Lundbeck focuses exclusively on brain diseases, specializing in the development and commercialization of therapies for conditions such as Alzheimer's, depression, and schizophrenia. It has over 70 years of neuroscience expertise.

Metric
Company Name	H. Lundbeck A/S	Capstone Advisors	Kalderos	Neuro Vigor Therapeutics
Symbol	LUN
MSH ID	COM:LUNDBECK	COM:CAPSTONEADVISORS	COM:KALDEROS	COM:NVTHERAPEUTICS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Real Estate	Healthcare & Health Services	Healthcare & Health Services
Industry	Drug Manufacturers - Specialty & Generic	Commercial Real Estate	Healthcare & Health Services	Biotechnology
Country	DK	US		US
Stage
Employee Count	5.35K		51
Website	lundbeck.com	capstoneadvisors.com	kalderos.com	nvtherapeutics.com
LinkedIn
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.82B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.18B
EBITDA	720.26M
Operating Income	452.47M
Net Income	324.30M
EPS	0.33
Diluted EPS	0.33
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.78
Operating Profit Margin	0.17
EBITDA Margin	0.26
Net Profit Margin	0.12
Return on Equity	0.11
Return on Assets	0.07
Return on Capital Employed	0.11

COM:LUNDBECK

Lundbeck

Last Close

171.10

01/01 00:00

Volume Today

346.95K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	26.03
P/B Ratio	1.88
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.89
EV Multiple	9.97

Metric
Days Sales Outstanding
Days Payables Outstanding	391.61
Days Inventory Outstanding	368.68
Operating Cycle	448.16
Cash Conversion Cycle	101.40
Asset Turnover	0.53

Metric
Operating Cash Flow	577.80M
Free Cash Flow	506.85M
Cash Flow to Debt	1.23
Operating Cash Flow/Sales	0.23
Free Cash Flow Yield

Metric
Cash & Equivalents	709.50M
Accounts Receivable	-23.65M
Inventory	626.94M
Goodwill	779.88M
Debt to Capitalization	0.23
Debt to Assets	0.15
Current Ratio	0.98
Quick Ratio	1.32

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.23
SG&A to Revenue	0.06